Omission of axillary dissection after a positive sentinel lymph-node: Implications in the multidisciplinary treatment of operable breast cancer.

[1]  R. Bast,et al.  Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Forbes,et al.  Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials , 2015, The Lancet.

[3]  Guangyu Liu,et al.  Predicting Non-sentinel Lymph Node Metastasis in a Chinese Breast Cancer Population with 1–2 Positive Sentinel Nodes: Development and Assessment of a New Predictive Nomogram , 2015, World Journal of Surgery.

[4]  E. van Limbergen,et al.  Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer. , 2015, The New England journal of medicine.

[5]  H. Struikmans,et al.  Regional Nodal Irradiation in Early-Stage Breast Cancer. , 2015, The New England journal of medicine.

[6]  S. Ohno,et al.  Clinical Significance of Extracapsular Invasion at Sentinel Lymph Nodes in Breast Cancer Patients with Sentinel Lymph Node Involvement , 2015, Annals of Surgical Oncology.

[7]  R. Gelber,et al.  Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  L. Pusztai,et al.  Multigene prognostic tests in breast cancer: past, present, future , 2015, Breast Cancer Research.

[9]  R. Jagsi,et al.  Radiation field design in the ACOSOG Z0011 (Alliance) Trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Bogaerts,et al.  Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. , 2014, The Lancet. Oncology.

[11]  E. Mccaig,et al.  Sentinel Node Biopsy Alone versus Completion Axillary Node Dissection in Node Positive Breast Cancer: Systematic Review and Meta-Analysis , 2014, International journal of breast cancer.

[12]  D. McMillan,et al.  Immunohistochemical detection improves the prognostic value of lymphatic and blood vessel invasion in primary ductal breast cancer , 2014, BMC Cancer.

[13]  Christos Sotiriou,et al.  Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  V. Peg,et al.  Nomogram including the total tumoral load in the sentinel nodes assessed by one-step nucleic acid amplification as a new factor for predicting nonsentinel lymph node metastasis in breast cancer patients , 2014, Breast Cancer Research and Treatment.

[15]  A. Sapino,et al.  A new clinical cut-off of cytokeratin 19 mRNA copy number in sentinel lymph node better identifies patients eligible for axillary lymph node dissection in breast cancer , 2014, Journal of Clinical Pathology.

[16]  A. Tőkés,et al.  In breast cancer patients sentinel lymph node metastasis characteristics predict further axillary involvement , 2014, Virchows Archiv.

[17]  M. Ernst,et al.  A Simple Risk Score to Predict the Presence of Non-Sentinel Lymph Node Metastases in Breast Cancer Patients with a Positive Sentinel Node , 2014, World Journal of Surgery.

[18]  M. Morrow,et al.  The Extent of Extracapsular Extension May Influence the Need for Axillary Lymph Node Dissection in Patients with T1–T2 Breast Cancer , 2014, Annals of Surgical Oncology.

[19]  S. Edge,et al.  Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  T. Reimer,et al.  Local Treatment of the Axilla in Early Breast Cancer: Concepts from the National Surgical Adjuvant Breast and Bowel Project B-04 to the Planned Intergroup Sentinel Mamma Trial , 2014, Breast Care.

[21]  Z. Winters,et al.  The real-time intra-operative evaluation of sentinel lymph nodes in breast cancer patients using One Step Nucleic Acid Amplification (OSNA) and implications for clinical decision-making. , 2014, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[22]  Helen G Mayo,et al.  Axillary node interventions in breast cancer: a systematic review. , 2013, JAMA.

[23]  D. Friedman,et al.  Predictive factors of non-sentinel lymph node involvement in patients with invasive breast cancer and sentinel node micrometastases. , 2013, Anticancer research.

[24]  V. Peg,et al.  Prediction of non-sentinel lymph node metastasis in early breast cancer by assessing total tumoral load in the sentinel lymph node by molecular assay. , 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[25]  A. Petit,et al.  Intraoperative molecular analysis of total tumor load in sentinel lymph node: a new predictor of axillary status in early breast cancer patients , 2013, Breast Cancer Research and Treatment.

[26]  T. Meretoja,et al.  International multicenter tool to predict the risk of four or more tumor-positive axillary lymph nodes in breast cancer patients with sentinel node macrometastases , 2013, Breast Cancer Research and Treatment.

[27]  A. Luini,et al.  Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. , 2013, The Lancet. Oncology.

[28]  F. Marandino,et al.  Quantitative Molecular Analysis of Sentinel Lymph Node May Be Predictive of Axillary Node Status in Breast Cancer Classified by Molecular Subtypes , 2013, PloS one.

[29]  A. Schneeweiss,et al.  Omission of Axillary Dissection According to ACOSOG Z0011: Impact on Adjuvant Treatment Recommendations , 2013, Annals of Surgical Oncology.

[30]  T. Meretoja,et al.  International multicenter tool to predict the risk of nonsentinel node metastases in breast cancer. , 2012, Journal of the National Cancer Institute.

[31]  R. Ponzone,et al.  Omission of Axillary Dissection after a Positive Sentinel Node Dissection may Influence Adjuvant Chemotherapy Indications in Operable Breast Cancer Patients , 2012, Annals of Surgical Oncology.

[32]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[33]  T. Meretoja,et al.  Multicentre validation of different predictive tools of non-sentinel lymph node involvement in breast cancer. , 2012, Surgical oncology.

[34]  A. Sapino,et al.  Reliability of Whole Sentinel Lymph Node Analysis by One-Step Nucleic Acid Amplification for Intraoperative Diagnosis of Breast Cancer Metastases , 2012, Annals of surgery.

[35]  P. V. van Diest,et al.  Regional Recurrence in Breast Cancer Patients With Sentinel Node Micrometastases and Isolated Tumor Cells , 2012, Annals of surgery.

[36]  F. Akiyama,et al.  Clinicopathological significance of invasive micropapillary carcinoma component in invasive breast carcinoma , 2011, Pathology international.

[37]  R. Greil,et al.  A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors , 2011, Clinical Cancer Research.

[38]  A. Giuliano,et al.  Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. , 2011, JAMA.

[39]  Donald L. Weaver,et al.  Effect of occult metastases on survival in node-negative breast cancer. , 2011, The New England journal of medicine.

[40]  T. Tot,et al.  Molecular Phenotypes of Unifocal, Multifocal, and Diffuse Invasive Breast Carcinomas , 2010, Pathology research international.

[41]  T. Julian,et al.  Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. , 2010, The Lancet. Oncology.

[42]  H. Kuerer,et al.  Trends in and Outcomes from Sentinel Lymph Node Biopsy (SLNB) Alone vs. SLNB with Axillary Lymph Node Dissection for Node-Positive Breast Cancer Patients: Experience from the SEER Database , 2010, Annals of Surgical Oncology.

[43]  Y. Suh,et al.  Predictors of axillary lymph node metastases (ALNM) in a Korean population with T1-2 breast carcinoma: triple negative breast cancer has a high incidence of ALNM irrespective of the tumor size. , 2010, Cancer research and treatment : official journal of Korean Cancer Association.

[44]  T. Fujii,et al.  Implication of Extracapsular Invasion of Sentinel Lymph Nodes in Breast Cancer: Prediction of Nonsentinel Lymph Node Metastasis , 2010, World Journal of Surgery.

[45]  D. Querleu,et al.  Factors predicting the sentinel node metastases in T1 breast cancer tumor: an analysis of 1416 cases. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[46]  A. Rademaker,et al.  Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. , 2009, Journal of Clinical Oncology.

[47]  Barbara L. Smith,et al.  Nomogram for the prediction of having four or more involved nodes for sentinel lymph node-positive breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  Solomon Henry,et al.  New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients , 2008, BMC Cancer.

[49]  A. Purushotham,et al.  A model for predicting non‐sentinel lymph node metastatic disease when the sentinel lymph node is positive , 2008, The British journal of surgery.

[50]  Xuesong Lu,et al.  Predicting features of breast cancer with gene expression patterns , 2008, Breast Cancer Research and Treatment.

[51]  Michael W Kattan,et al.  Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  H. Tsuda,et al.  One-step Nucleic Acid Amplification for Intraoperative Detection of Lymph Node Metastasis in Breast Cancer Patients , 2007, Clinical Cancer Research.

[53]  U. Chetty,et al.  Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. , 2006, Journal of the National Cancer Institute.

[54]  Tanya Hoskin,et al.  Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram. , 2005, American journal of surgery.

[55]  F. Montemurro,et al.  Controversies in breast cancer: adjuvant and neoadjuvant therapy , 2005, Expert opinion on pharmacotherapy.

[56]  Antoine Flahault,et al.  An axilla scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement , 2005, Breast Cancer Research and Treatment.

[57]  David Bouwman,et al.  Correlation of tumor volume and surface area with lymph node status in patients with multifocal/multicentric breast carcinoma , 2004, Cancer.

[58]  J. Peterse,et al.  Discrepancies in current practice of pathological evaluation of sentinel lymph nodes in breast cancer. Results of a questionnaire based survey by the European Working Group for Breast Screening Pathology , 2004, Journal of Clinical Pathology.

[59]  C. Manivel,et al.  Invasive micropapillary carcinoma of the breast: clinicopathologic study of 62 cases of a poorly recognized variant with highly aggressive behavior. , 2004, American journal of clinical pathology.

[60]  Hiram S. Cody,et al.  A Nomogram for Predicting the Likelihood of Additional Nodal Metastases in Breast Cancer Patients With a Positive Sentinel Node Biopsy , 2003, Annals of Surgical Oncology.

[61]  Kelly K. Hunt,et al.  Clinicopathologic Factors Predicting Involvement of Nonsentinel Axillary Nodes in Women With Breast Cancer , 2003, Annals of Surgical Oncology.

[62]  D. Visscher,et al.  Clinicopathologic Analysis of Invasive Micropapillary Differentiation in Breast Carcinoma , 2001, Modern Pathology.

[63]  I. Bleiweiss,et al.  Invasive micropapillary carcinoma of the breast: eighty cases of an underrecognized entity. , 2001, Human pathology.

[64]  D. Reintgen,et al.  Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla: a study to evaluate the need for complete axillary lymph node dissection. , 2001, Archives of surgery.

[65]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[66]  I. Bleiweiss,et al.  Lymphatic invasion, tumor size, and age are independent predictors of axillary lymph node metastases in women with T1 breast cancers. , 1999, Annals of surgery.

[67]  J. Donohue,et al.  Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer? , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  A. Giuliano,et al.  Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. , 1997, Annals of surgery.

[69]  C. Carter,et al.  Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases , 1989, Cancer.

[70]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[71]  M. Ellis,et al.  Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer. , 2015, The New England journal of medicine.

[72]  Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death , 2013 .

[73]  R. Fábregas,et al.  Complete Axillary Lymph Node Dissection Versus Clinical Follow-up in Breast Cancer Patients with Sentinel Node Micrometastasis: Final Results from the Multicenter Clinical Trial AATRM 048/13/2000 , 2012, Annals of Surgical Oncology.

[74]  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials , 2012 .

[75]  A. Soran,et al.  Validation of breast cancer nomograms for predicting the non-sentinel lymph node metastases after a positive sentinel lymph node biopsy in a multi-center study. , 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[76]  Robert B Livingston,et al.  Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. , 2010, The Lancet. Oncology.

[77]  K. Griffith,et al.  Clinicopathologic Features Associated With Having Four or More Metastatic Axillary Nodes in Breast Cancer Patients With a Positive Sentinel Lymph Node , 2006, Annals of Surgical Oncology.

[78]  M. Silverstein,et al.  Predictors of axillary lymph node metastases in patients with T1 breast carcinoma , 1997, Cancer.